Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle‐related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences. Issue 7 (23rd May 2022)

• Record Type: Journal Article
• Authors: Xu, Yanhui; Qi, Wenqian; Wang, Xu; Zhang, Yonggui; Han, Liang; Shi, Jingyi; Wang, Guohua; Liu, Jia; Duan, Honglei; Cong, Xianling; Zhao, Ping; Zhou, Changyu; Wang, Jiangbin
• Is Part Of: Journal of viral hepatitis. Volume 29:Issue 7(2022)
• Page Start: 569
• Page End: 578
• Publication Date: 2022-05-23
• Subjects: androgen receptor -- cell cycle‐related kinase -- chronic HBV infection -- gender differences -- signal transducer and activator of transcription 3; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13699
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: The study aimed to investigate the role of androgen receptor (AR)/cell cycle‐related kinase (CCRK) signalling pathway in chronic hepatitis B virus (HBV) infection and gender differences, and the contribution of AR regulatory factor signal transducer and activator of transcription 3 (STAT3) in it. AR, CCRK, and phosphorylated STAT3 expressions in liver tissues of chronic HBV‐infected patients and non‐HBV controls were determined by western blot and compared between genders. The relationships of expression levels with serum HBV DNA levels, liver inflammation activity, and fibrosis score were analysed in chronic HBV‐infected patients. The relationships between expression levels of three proteins were also analysed. HBV‐infected patients had significantly higher expression levels of AR, CCRK, and p‐STAT3 Tyr705 compared with controls ( p < .01). The expression levels of AR, CCRK, and p‐STAT3 Tyr705 in chronic HBV‐infected patients with severe inflammation were significantly higher than those with mild inflammation ( p < .05). Expression levels in patients with heavier fibrosis (stage F4) were higher than in those with less fibrosis (stages F0–3) ( p < .01). No gender differences were observed in AR, CCRK, and p‐STAT3 Tyr705 levels in non‐HBV controls; higher levels were observed in HBV‐infected males than in HBV‐infected females ( p < .05). AR, CCRK, and p‐STAT3 Tyr705 levels in liver tissues positively correlated with each other ( p < .0001) and with serum HBV DNA levels ( p < .0001). In conclusion, in this study, we first found concordant over‐expression of AR, CCRK, and STAT3 in liver tissues of chronic HBV‐infected patients who have not yet developed HCC, significantly correlated with the severity of the disease and showed gender differences. STAT3 may be a potential therapeutic co‐target for chronic HBV infection.